Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 29, 2024--
HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients an up to Once-Monthly Treatment...
Takeda TSE4502NYSETAK today announced that the European Commission EC approved HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy CIDP after stabilization with intravenous immunoglobulin therapy IVIG.
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients…
Novotech today released the latest 2023 global clinical trial landscape report on HIV, a condition now affecting more than 39 million people....